Download PDF
Der Klinikarzt 2020; 49(11): 468-482
DOI: 10.1055/a-1298-3661
Schwerpunkt

Standard Changing News der Senologie und der Gynäkologischen Onkologie 2020

Mammakarzinom, Ovarialkarzinom, Zervixkarzinom und Endometriumkarzinom: Neue Entwicklungen und aktuelle wissenschaftliche Daten
Caroline Preuß∗
1   Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, Friedrich-Alexander University Erlangen-Nürnberg (FAU)
,
Alexander Hein
1   Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, Friedrich-Alexander University Erlangen-Nürnberg (FAU)
,
Matthias W. Beckmann
1   Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, Friedrich-Alexander University Erlangen-Nürnberg (FAU)
,
Sebastian M. Jud
1   Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, Friedrich-Alexander University Erlangen-Nürnberg (FAU)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Viele Publikationen machten das onkologische Jahr 2019/2020 wieder zu einem spannenden und hoffnungsvollen Jahr im Bereich der Senologie und der Gynäkologischen Onkologie. Die großen onkologischen Kongresse ESMO und das San Antonio Breast Cancer Symposium fanden im Herbst 2019 noch in gewohnter Form statt, während das ASCO Annual Meeting im Mai 2020 aufgrund der weltweiten Corona-Pandemie als virtueller Kongress stattfand.

Weiterhin sind individuelle Therapiekonzepte im Sinne einer personalisierten Medizin der richtungsweisende Trend. Therapieentscheidungen basieren neben individuellen Patientenfaktoren zunehmend auf der Grundlage molekularpathologischer und genetischer Tumoreigenschaften. Zielgerichtete Tumortherapien verdrängen immer mehr die „klassischen“ Chemotherapien oder ergänzen diese zum Beispiel als Erhaltungstherapie nach Ansprechen auf eine Chemotherapie. Die Tumortherapien müssen sich nicht mehr „nur“ an ihrer antitumorösen Wirksamkeit wie Overall survival (OS) oder Progression free survival (PFS) messen lassen, sondern auch an ihrer Verträglichkeit für die Patienten, dem Nebenwirkungsspektrum und der Lebensqualität der Patienten.

Der folgende Artikel soll gegliedert in Mammakarzinom, Ovarialkarzinom, Zervixkarzinom und Endometriumkarzinom einen Überblick über die neuesten Entwicklungen und aktuellsten wissenschaftlichen Daten des jeweiligen Malignoms vermitteln. Die wichtigsten Key Massages sind am Ende des jeweiligen Abschnittes zusammengefasst.



Publication History

Article published online:
25 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. 2017 AWMF Registernummer: 032-045OL, Version 4.0, 2017
    PubMed
  • 2 Voort v.d. A, Ramshorst van MS, Werkhoven van ED. et al Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. Journal of Clinical Oncology 2020; 38 (Suppl. 15) 501-501
    CrossrefPubMedGoogle Scholar
  • 3 Schmid P, Cortes J, Pusztai L. et al Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382: 810-821
    CrossrefPubMedGoogle Scholar
  • 4 Fasching PA, Jackisch C, Rhiem K. et al GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J Clin Oncol 2019; 37 (Suppl. 15) 506-506
    CrossrefPubMedGoogle Scholar
  • 5 Wang X, Wang SS, Huang H. et al Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001). J Clin Oncol 2020; 38 (Suppl. 15) 507-507
    CrossrefPubMedGoogle Scholar
  • 6 Masuda N, Lee SJ, Ohtani S. et al Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376: 2147-2159
    CrossrefPubMedGoogle Scholar
  • 7 Fehm T. Adjuvante zytostatische und zielgerichtete Therapien. 2020. Guidlines Breast 2020 1D 9
    PubMedGoogle Scholar
  • 8 von Minckwitz G, Huang CS, Mano MS. et al Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2018; 380: 617-628
    CrossrefPubMedGoogle Scholar
  • 9 Cardoso F, van’t Veer LJ, Bogaerts J. et al 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-729
    CrossrefPubMedGoogle Scholar
  • 10 Cardoso F, van’t Veer L, Poncet C. et al MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. J Clin Oncol 2020; 38 (Suppl. 15) 506-506
    CrossrefPubMedGoogle Scholar
  • 11 Gemeinsamer Bundesausschuss. Methodenbewertung – Unterstützung der Therapieentscheidung bei Brustkrebs im Frühstadium: Biomarker-Test künftig Kassenleistung. 2019
    PubMedGoogle Scholar
  • 12 Khan SA, Zhao F, Solin LJ. et al A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol 2020; 38 (Suppl. 18) LBA2-LBA2
    CrossrefPubMedGoogle Scholar
  • 13 Turner NC, Slamon DJ, Ro J. et al Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936
    CrossrefPubMedGoogle Scholar
  • 14 Sledge GW, Toi M, Neven P. et al MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884
    CrossrefPubMedGoogle Scholar
  • 15 Sledge GW, Toi M, Neven P. et al The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy – MONARCH 2: A Randomized Clinical Trial. JAMA Oncology 2020; 6: 116-124
    CrossrefPubMedGoogle Scholar
  • 16 Tripathy D, Im SA, Colleoni M. et al Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-915
    CrossrefPubMedGoogle Scholar
  • 17 Im SA, Lu YS, Bardia A. et al Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
    CrossrefPubMedGoogle Scholar
  • 18 Slamon DJ, Neven P, Chia S. et al Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
    CrossrefPubMedGoogle Scholar
  • 19 Wander SA, Zangardi M, Niemierko A. et al A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2– metastatic breast cancer (MBC). J Clin Oncol 2019; 37 suppl; abstr 1057 2019
    CrossrefPubMedGoogle Scholar
  • 20 Tamragouri K, Cobleigh MA, Rao RD. Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib. J Clin Oncol 2019; 37 suppl; abstr e12533 2019
    CrossrefPubMedGoogle Scholar
  • 21 André F, Ciruelos E, Rubovszky G. et al Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
    CrossrefPubMedGoogle Scholar
  • 22 Rugo HS, Lerebours F, Ciruelos E. et al Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. J Clin Oncol 2020; 38 (Suppl. 15) 1006-1006
    CrossrefPubMedGoogle Scholar
  • 23 Schmid P, Rugo HS, Cortes J. et al XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement. J Clin Oncol 2019; 37 (suppl; abstr TPS1103) 2019
    CrossrefPubMedGoogle Scholar
  • 24 Bardia A, Aftimos PG, Jiang H. et al EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2– advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy. J Clin Oncol 2019; 37 (suppl; abstr TPS1104) 2019
    CrossrefPubMedGoogle Scholar
  • 25 Robson ME, Tung N, Conte P. et al OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30: 558-566
    CrossrefPubMedGoogle Scholar
  • 26 Litton JK, Rugo HS, Ettl J. et al Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379: 753-763
    CrossrefPubMedGoogle Scholar
  • 27 Robson M, Im SA, Senkus E. et al Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research 2020; 80 (Suppl. 04) PD4-03-PD4-03
    CrossrefPubMedGoogle Scholar
  • 28 Tung NM, Robson ME, Ventz S. et al TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). J Clin Oncol 2020; 38 (Suppl. 15) 1002-1002
    CrossrefPubMedGoogle Scholar
  • 29 Sharma P, Rodler E, Barlow WE. et al Results of a phase II randomized trial of cisplatin ± veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416). Journal of Clinical Oncology 2020; 38 (Suppl. 15) 1001-1001
    CrossrefPubMedGoogle Scholar
  • 30 Swain SM, Baselga J, Kim SB. et al Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med 2015; 372: 724-734
    CrossrefPubMedGoogle Scholar
  • 31 Swain SM, Miles D, Kim SB. et al End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2019; 37 (suppl; abstr 1020) 2019
    CrossrefPubMedGoogle Scholar
  • 32 Diéras V, Miles D, Verma S. et al Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 732-742
    CrossrefPubMedGoogle Scholar
  • 33 Murthy RK, Loi S, Okines A. et al Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
    CrossrefPubMedGoogle Scholar
  • 34 Rugo HS, Im SA, Cardoso F. et al Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Cancer Research 2020; 80 (Suppl. 04) GS1-02-GS1-02
    CrossrefPubMedGoogle Scholar
  • 35 Schmid P, Adams S, Rugo HS. et al IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2019; 37 (suppl; abstr 1003) 2019
    CrossrefPubMedGoogle Scholar
  • 36 Cortes J, Cescon DW, Rugo HS. et al KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol 2020; 38 (Suppl. 15) 1000-1000
    CrossrefPubMedGoogle Scholar
  • 37 Bois AD, Cescon DW, Rugo HS. et al Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol 2020; 38 (Suppl. 15) 6000
    CrossrefPubMedGoogle Scholar
  • 38 Moore K, Colombo N, Scambia G. et al Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018; 379: 2495-2505
    CrossrefPubMedGoogle Scholar
  • 39 Fujiwara K, Harter P, Leary A. et al Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology 2019; 30: ix191-ix192
    CrossrefPubMedGoogle Scholar
  • 40 González-Martín A, Pothuri B, Vergote I. et al Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019; 381: 2391-2402
    CrossrefPubMedGoogle Scholar
  • 41 Coleman RL, Fleming GF, Brady MF. et al Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med 2019; 381: 2403-2415
    CrossrefPubMedGoogle Scholar
  • 42 Gershenson DM, Miller A, Brady W. et al A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. Annals of Oncology 2019; 30: v897-v898
    CrossrefPubMedGoogle Scholar
  • 43 Mathevet P, Lecuru F, Magaud L. et al Sentinel lymph node biopsy for early cervical cancer: Results of a randomized prospective, multicenter study (Senticol 2) comparing adding pelvic lymph node dissection vs sentinel node biopsy only. Gynecologic Oncology 2017; 145: 2-3
    CrossrefPubMedGoogle Scholar
  • 44 Balaya V, Guani B, Magaud L. et al Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer. Journal of Clinical Oncology 2020; 38 (Suppl. 15) 6006-6006
    CrossrefPubMedGoogle Scholar
  • 45 Huang H, Feng Y, Ting T. et al Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial. Journal of Clinical Oncology 2020; 38 (Suppl. 15) 6007-6007
    CrossrefPubMedGoogle Scholar
  • 46 Naumann RW, Oaknin A, Meyer T. et al Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358. Annals of Oncology 2019; 30: v898-v899
    CrossrefPubMedGoogle Scholar
  • 47 Nomura H, Aoki D, Michimae H. et al A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043). J Clin Oncol 2017; 35 (Suppl. 15) 5503-5503
    CrossrefPubMedGoogle Scholar
  • 48 Makker V, Taylor MH, Aghajanian C. et al Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC). Annals of Oncology 2019; 30: v404-v405
    CrossrefPubMedGoogle Scholar
  • 49 Makker V, Rasco D, Vogelzang NJ. et al Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019; 20: 711-718
    CrossrefPubMedGoogle Scholar
  • 50 de Boer SM, Powell ME, Mileshkin L. et al Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 295-309
    CrossrefPubMedGoogle Scholar
  • 51 Matei D, Filiaci V, Randall ME. et al Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 2019; 380: 2317-2326
    CrossrefPubMedGoogle Scholar